Hydrogen peroxide
As of the edition of 20 October 2026, Hydrogen peroxide is a small molecule: marketed, first approved in 2017 (US); no US protection is listed.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2017
- Kind
- Small molecule
- Brand name
- Eskata
- First approved
- 14 December 2017 (US)
- Approvals on record
- 1 in 1 region
- Holder of the most recent approval
- Aclaris Therapeutics
- Registered trials
- 34, 2 stopped early
- Disease areas
- Skin and connective tissue; Infections; Mouth and teeth; Cancer; Lungs and airways; Immune system
US protection
No US protection is listed.
The FDA registers list no drug-substance patent or exclusivity that counts for this drug.
This is the US only.
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 11 | 7 | 4 | 0 |
| Phase 1 | 3 | 3 | 0 | 0 |
| Phase 2 | 9 | 6 | 1 | 1 |
| Phase 3 | 7 | 6 | 1 | 0 |
| Phase 4 | 4 | 3 | 0 | 1 |
| All trials | 34 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Aclaris Therapeutics | Originator and Lead sponsor of trials | 2015 to now |